Summit Therapeutics (SMMT) Expected to Announce Earnings on Thursday

Key Points

• Summit Therapeutics is expected to report Q1 2026 results before the market opens on May 7, with analysts forecasting ($0.30) EPS and $0.99 million in revenue after the company missed estimates last quarter.
• Shares trade around $20.83 with a market capitalization of $16.17 billion, and the consensus analyst rating is a Moderate Buy with an average target price of $31.00.
• Institutional activity has increased recently — notably Price T. Rowe Associates more than doubled its stake to 9.37 million shares — while institutions collectively own about 4.61% of the stock.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $0.99 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.07). On average, analysts expect Summit Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Summit Therapeutics Price Performance

Shares of Summit Therapeutics stock opened at $20.83 on Thursday. The firm has a market capitalization of $16.17 billion, a PE ratio of -14.37 and a beta of -1.36. The company's fifty day moving average price is $18.32 and its two-hundred day moving average price is $17.84. Summit Therapeutics has a 52-week low of $13.83 and a 52-week high of $30.98.

Institutional Investors Weigh In On Summit Therapeutics

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Summit Therapeutics by 106.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,371,415 shares of the company's stock worth $163,907,000 after purchasing an additional 4,832,592 shares during the last quarter. State Street Corp grew its holdings in shares of Summit Therapeutics by 4.3% in the 4th quarter. State Street Corp now owns 6,636,361 shares of the company's stock worth $116,070,000 after purchasing an additional 274,425 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Summit Therapeutics by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,147,480 shares of the company's stock worth $55,063,000 after purchasing an additional 14,745 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Summit Therapeutics by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 892,629 shares of the company's stock worth $15,612,000 after purchasing an additional 16,239 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Summit Therapeutics by 16.1% in the 3rd quarter. Bank of America Corp DE now owns 657,313 shares of the company's stock worth $13,580,000 after purchasing an additional 91,166 shares during the last quarter. Institutional investors own 4.61% of the company's stock.

Analyst Ratings Changes

SMMT has been the topic of several analyst reports. HC Wainwright lowered their price target on shares of Summit Therapeutics from $40.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 24th. Citizens Jmp reissued a "market outperform" rating and issued a $40.00 price target on shares of Summit Therapeutics in a report on Friday, January 30th. Jefferies Financial Group lowered shares of Summit Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $42.00 to $15.00 in a report on Monday, March 16th. Stifel Nicolaus initiated coverage on shares of Summit Therapeutics in a report on Wednesday, April 8th. They issued a "buy" rating and a $45.00 price target on the stock. Finally, Citigroup initiated coverage on shares of Summit Therapeutics in a report on Wednesday, April 8th. They issued a "buy" rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.